Celadon becomes Celadon Pharmaceuticals Plc in its admission the AIM market on the London Stock Exchange
Celadon is this morning delighted to announce its admission to the London Stock Exchange AIM market, raising £8.5m and bringing the total raise in the past year to ~£20m.
Our goal is to become the provider and partner of choice for researching and producing pharmaceutical-grade cannabinoid-based medicines. We have built an integrated supply chain and have received the relevant licencing from the UK governance to cultivate high-THC medical cannabis in our 100,000 sq ft UK facility, including a UK GMP-designed laboratory.
With an MHRA conditionally approved trial for cannabinoid-based medicinal products for chronic pain, we have ambitious plans for Celadon Pharmaceuticals Plc.